SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/7BBEC73C963679CE2E3DDFF1B1BE20B4AAC4ED0D17DAF31E62605B13EB9F3927F5246D889C541B340B03CC5A86117AC2>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/7BBEC73C963679CE2E3DDFF1B1BE20B4AAC4ED0D17DAF31E62605B13EB9F3927F5246D889C541B340B03CC5A86117AC2
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/7BBEC73C963679CE2E3DDFF1B1BE20B4AAC4ED0D17DAF31E62605B13EB9F3927F5246D889C541B340B03CC5A86117AC2
http://www.w3.org/2000/01/rdf-schema#comment
"Class III beta-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer."
xsd:string
http://purl.uniprot.org/uniprot/#_6C302E04AC8AA0952D3F306091C082002C66C0320B8ED9E86542EF32F2C8B9D76C8BC67F0CECAAEA3BB1D308A888ED72
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/7BBEC73C963679CE2E3DDFF1B1BE20B4AAC4ED0D17DAF31E62605B13EB9F3927F5246D889C541B340B03CC5A86117AC2
http://purl.uniprot.org/uniprot/Q6PJ87
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/7BBEC73C963679CE2E3DDFF1B1BE20B4AAC4ED0D17DAF31E62605B13EB9F3927F5246D889C541B340B03CC5A86117AC2
http://purl.uniprot.org/uniprot/#_Q6PJ87-mappedCitation-35695793
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/7BBEC73C963679CE2E3DDFF1B1BE20B4AAC4ED0D17DAF31E62605B13EB9F3927F5246D889C541B340B03CC5A86117AC2